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Abstrak ( Versi bahasa Melayu ) 
Latar belakang : Penyakit sumbatan paru-paru kronik bukannya hanya 
berkaitan dengan paru-paru sahaja tetapi ia mempunyai manifestasi menyeluruh 
disebabkan proses keradangan yang menjadi penyebab penyakit ini berlaku. Ukuran 
komposisi badan (indeks jisim tubuh dan indeks jisim tubuh bebas lemak) sebagai 
manifestasi menyeluruh penyakit ini telah menunjukkan bahawa ia berkait rapat 
dengan kadar keterukan dan kematian kepada pesakit.  
Objektif utama kajian ini adalah untuk melihat kaitan antara komposisi badan 
dengan tahap keterukan pesakit sumbatan paru-paru kronik yang stabil (tidak 
mengalami keterukan yang bertambah dalam jangkamasa tiga bulan sebelum 
kajian). 
Kaedah : Kami mengkaji 38 pesakit paru-paru kronik stabil yang datang ke 
klinik paru-paru HUSM dan mengukur indek jisim tubuh, indek jisim tubuh bebas 
lemak, ujian berjalan selama enam minit dan ujian darah untuk CRP.  
Keputusan : Kajian ini menunjukkan perbezaan ukuran komposisi badan tidak 
mempunyai kaitan dengan tahap keterukan penyakit sumbatan paru-paru kronik 
yang stabil (p > 0.05). 
Kesimpulan : Ukuran komposisi badan tidak boleh digunakan untuk 
menilai tahap keterukan pesakit paru-paru kronik yang stabil. 
 
 
 
x 
 
Abstract (English version) 
Background: COPD is not just a disease of the lungs alone; it has systemic 
manifestations due to the underlying pathogenesis of inflammatory reaction. 
Systemic manifestations in term of reduction in body composition (Body Mass Index 
and Fat Free Mass Index) has been shown to be an independent risk factor for 
disease severity and mortality in COPD.  
The objective of this study is to determine the association of body composition 
with disease severity in stable COPD patients (patients who had no exacerbation in 
the past three months).   
Methods: We evaluated 38 stable COPD patients attending Respiratory Clinic 
in HUSM and calculated their Body Mass Index, Fat Free Mass Index and 
determined their six minutes walking distance and serum CRP values.  
Results: There was no satisfactory significant difference between body 
composition and disease severity in COPD patients noted in this study ( p > 0.05 ).  
Conclusion: Body composition (BMI,FFMI) is not suitable for assessment of 
disease severity in stable COPD patients.  
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1. Introduction 
 
  Chronic Obstructive Pulmonary Disease (COPD) is one of the most common 
respiratory disorder that effect many people worldwide besides asthma, common cold 
and chest infections. One of the major leading worldwide work in this illness is the 
Global Initiative of Chronic Obstructive Lung Disease (GOLD), that is been conducted 
by the World Health Organization. They had produced a guideline to define and 
further manage COPD. The GOLD guideline had been accepted worldwide including 
in Malaysia whereby base on it, Malaysia has produce its own guideline in 2009 
under the Malaysian Clinical Practice Guideline by the Ministry of Health. All this is 
done to improve and educate health care professional to manage patient 
appropriately. 
 The definition by GOLD guideline updated in 2010 had included that COPD 
have significant extra pulmonary manifestations which may contribute to the severity 
of the disease. The systemic illnesses for example are nutritional abnormality (Daniel 
A King et al., 2008), weight loss and skeletal muscle depletion (M. Jeffery Mador and 
Boskanat., 2001), osteoporosis (Lidwien Graat-Verboom et al., 2009), depression 
(Wanning Xu et al., 2008) and anaemia (T. Similowski et al., 2006).    
 The extra pulmonary manifestation of COPD will be the main focus of this 
study whereby its association with COPD severity based on the lung fuction test will 
be assessed. The extra pulmonary manifestation that will be look into is the body 
composition. This is because based on the previous study, body composition had 
been shown to be an independent predictor of disease severity and mortality(Jorgen 
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Vestbo et al., 2006). This is the main evaluation that will be observed in this study as 
to further confirm the previous finding to our local data in Malaysia. 
 From this study, hopefully the use of body composition as one of the 
assessments in prevention and treatment of COPD will be established. Another 
aspect that would be assesses in this study is patient’s functional capacity according 
to their severity of COPD. This is important because body composition was noted to 
have a significant correlation with exercise capacity in COPD patients (Eleni Ischaki 
et al., 2007). 
 As for the underlying cause of the extra pulmonary manifestation of COPD, 
this study will look into the role of C-reactive protein as the inflammatory marker to 
predict the COPD severity. Systemic inflammation had been shown to be the 
underlying pathogenesis of COPD and few inflammatory markers was observed to be 
elevated in COPD including CRP(Abdullah A. eid et al., 2001). 
 In conclusion, hopefully from this study data, we could determine the 
correlation between body composition and disease severity in COPD patients that 
might be helpful in managing COPD patient rather than concentrating on their 
respiratory symptoms alone. Further pulmonary rehabilitation or nutritional point of 
view might be considered to help improving patient’s quality of life and also in 
reducing the mortality related to the illness. 
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2. Literature review 
2.1 Definition: 
In 2006, the Global Initiative of Chronic Obstructive Airway Disease( GOLD ) 
had produced a guideline for chronic obstructive airway disease ( COPD ) and 
defined it as “Preventable and treatable disease with some significant 
extrapulmonary effects that may contribute to the severity in individual patients. The 
airflow limitations is usually progressive and associated with an abnormal inflamatory 
response of the lung to noxious particle”. In the updated version of 2010 this 
definition remains unchanged. Worlwide, ciggarete smoking is the most commonly 
encountered risk factor for COPD, although in many countries, air pollution resulting 
from the burning of wood and other biomass fuels has also been identified as a 
COPD risk factor(Nanshan Zhong et al., 2007) 
The primary physiological abnormality in COPD is an accelerated decline in 
the forced expiratory volume in one second(FEV1). FEV1 is defined as the maximal 
air of a person can exhaled in one second and will shows the degree of airway 
obstruction. The COPD symptoms starts from asymptomatic phase in which lung 
function deteriorates without associated symptoms. The onset of the subsequent 
symptomatic phase is variable and usually starts when the FEV1 fall to less than 
50%. 
 
2.2 Global Initiative of Chronic Lung Disease (GOLD) guideline : 
The GOLD guideline was initiated in 1998 by the World Health Organization to 
bring more attention and awareness to COPD, its management and its prevention. 
Therefore it can reduced the morbidity and mortality due to chronic obstructive airway 
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disease. The first GOLD guideline was published in 2001, and since then continous 
work were been done to update the guideline yearly by the corresponding commity. 
This is because eventhough COPD is considered a major public health problem, its 
awareness among the public are still low as compared to other non communicable 
disease such as diabetes mellitus, hypertension or ischaemic heart disease (Barbara 
P Yawn and Wollan., 2008). The nihilistic attidude among some health care providers 
towards managing COPD are still present due to the dissapointment in improving 
patient symptoms despite the treatment given ( GOLD guideline updated version 
2010 ). 
 
2.3 Prevalance and burden of COPD : 
The prevalance of COPD varies in between countries. In year 2006 a meta-
analysis of 37 studies showed that the pooled prevalance was estimated at 7.6% of 
the general population(R.J. Halbert et al., 2006) worlwide. In Malaysia, based on the 
regional working group 2009, the prevalance of moderate to severe COPD patients 
age 30 years or above is estimated at 4.55%. The Global burden of disease study 
has estimated that by the year 2020, COPD would be ranked as the third leading 
cause of death just after ischaemic heat disease and cerebrovascular accident 
(Christopher J L Murray and Lopez, 1997). This had made it moving three steps 
further as it is just ranked at number 6th in year 1990. The prevalance and burden of 
COPD are projected to increase in the coming decades due to continued exposure to 
COPD risk factor and the changing age structure of the world’s population. In 2007 
alone, according to World Health Organization, 210 million people have COPD 
worlwide with 80 million of them experiencing moderate to severe chronic disease 
(Mathers C). 
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Its going to be challenging as this disease is related to lifestyle especially 
smoking as the incidence of smoking is increasing and as also as  increasing age of 
the population(Chen JC and DM., 1999). It would be a burden to patient as it would 
be a condition of chronic disability and a burden to the country to manage COPD. 
Approximately in year 2000, 2.7 million deaths occurred due to COPD and more than 
half of it ocurrs in the Asia-Pasific region including Malaysia(A.d. Lopez et al., 2006). 
 
2.4 Airflow limitations in COPD  
The airflow limitations in COPD is due to a mixture of small airway disease ( 
chronic bronchitis ) and lung parenchymal destruction( emphysema ). It is associated 
with abnormal inflammatory reactions towards noxius particles or gases. The most 
common noxious particle is from ciggerates smoking and if the exposures remained it 
will progressively worsening (A Sonia Buist et al., 2007). Chronic airway 
inflammations causes changes and narrowing of the small airways and this leads to 
loss of the alveolar attachments to the small airways. Because of this there is a 
decreases in the lung elastic recoil that diminishes the ability of the airways to remain 
open during expiration. The airway limitations is measured by using the coventional 
lung function test which is the spirometry test (Nilva Regina Gelamo Pelelegrino et 
al., 2009). 
 
2.5 Risk factor for developing COPD : 
 There are multiple risk factor that would contribute to the developement of 
COPD including genetics, exposure to noxious particles ( eg : tobacco smokes, 
organic and inorganic occupational dust ), lung growth and development, oxidative 
stress, gender, age, respiratory infections and socioeconomic status. 
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2.5.1 Tobacco smoke 
 It is estimated that only 15% of smokers develop COPD (A Løkke et al., 2006), 
however 90% of the cases of COPD have smoking as their risk factor. This shows 
that there are other factors contributing to the development of COPD. World Health 
organization estimates that in high-income countries, 73% of COPD mortality is 
related to smoking, while in low and middle income countries the rate is 40% (A.d. 
Lopez et al., 2006). Back in 1977, Burrow (Burrow., 1977) has already shown that in 
a study of general population, there is a highly significant quantitative relationships 
between pack years of smoking and fucntional impairment of the FEV1.  
 Smoking prevention is the most effective intervention to reduce the risk of 
developing COPD and stop its progression. Smoking cessation has been shown that 
it would reduced inflammatory markers both in patient with or without having chronic 
respiratory symptom(B.W.M. Willemse et al., 2004). Stopping from tobacco smokes 
also been shown to result in a sustained 50% reduction in the rate of lung function 
decline in patient with COPD(Nicholas R. Anthonisen et al., 2002). In the lung health 
study, Anthonisen showed that men who stopped smoking at the beginning of the 
study and follow up over the 11 years period had a decline of FEV1 rate of 30.2 
ml/year compared to those who continue smoking had an FEV1 declined at rate of 
66.1 ml/year. This was also true in women where the reduction was 21.5 ml/years in 
those who stopped smoking versus 54.2ml/year in those who continued smoking. 
 
2.5.2 Occupational exposure 
 According to American thoracic Society statement in 2003 (J.Balmes et al., 
2003) occupational exposure may attributed to COPD in 15% of smokers and 31% of 
non smokers. Occupational exposure to dust, gas and fumes may cause chronic 
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bronchitis, chronic emphysema, and irreversible airflow obstruction and studies from 
both population based and occupational cohort have shown that occupational 
exposure is associated with an increased incidence of COPD irrespective of smoking 
(Esther Rodríguez et al., 2008).  
 
2.5.3 Genetics 
 Genetics susceptibility to developed COPD was instituted by the data that only 
a minority of cigarette smokers developed COPD. The effects of smoking to lung 
function in monozygotic and dizygotic twins shows that when one monozygotic twin 
was susceptible to the effects of cigarette smoke, both twins developed reductions in 
lung function, whereas other monozygotic twin pairs appeared to be non susceptible 
and, despite similar smoking intensity, maintained normal function(Webster PM et al., 
1979). Studies of families and twins suggest that genetic factors also contribute to the 
development of COPD. The only established genetic risk factor for COPD is 
homozygosity for the Z allele of the alfa-1 antitrypsin gene(A.J. Sandford et al., 
1997). Polymorphism for the genes including alpha 1-antichymotrypsin, vitamin D-
binding protein, microsomal epoxide hydrolase, cytochrome P450 1A1, Glutathione 
S-transferase and immunoglobulin A, have also been associated with the 
development of COPD(Miki M and k., 1999). 
 
2.6 Diagnosing and assessing COPD severity 
 The diagnosis of COPD must be considered in patient who has symptoms of 
dyspnoea, chronic cough or sputum production with history of exposure to risk factors 
for the disease especially to cigarette smoking. Spirometry test is important for 
confirmation of COPD and it provides a useful description of the severity of the 
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airflow obstruction in COPD. Spirometry should be done after an adequate dose of 
an inhaled bronchodilator to minimise the variability and exclude asthma(Pellegrino R 
et al., 2005). A study in a random population sample (Johannessen A et al., 2006) 
found the post bronchodilator FEV1/FVC exceeded 70% in all age groups, supporting 
the use of this fixed ratio to diagnosed airway obstruction.  
 
2.6.1 Spirometry test 
 In staging the severity of COPD the Malaysian COPD guideline 2009 had 
followed the GOLD guideline 2006 that it is being classified into four groups 
according to the post bronchodilator forced expiratory volume in one second (FEV1): 
 Stage 1: mild   FEV1 >80 % predicted 
 Stage 2: moderate  50 % < FEV1 < 805 predicted 
Stage 3 : severe 30 % < FEV1 < 50% predicted 
Stage 4 : very severe FEV1 < 30 % predicted or FEV1 < 50 % predicted  
plus chronic respiratory failure. 
 However the relationship between the degrees of limitation based on the 
spirometry alone is not perfect. The degree of dyspnoea and disability should also be  
use to asses severity which reflects the overall disease impact (D A Mahler and 
Wells., 1988) such as by using the Modified Medical Research Council (MMRC) 
dyspnoea scale as suggested in the Malaysian Guideline 2009.  
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Table 1: The Modified Medical Research Council (MMRC) Dyspnoea Scale: 
Grade of dyspnoea Description 
0 Not troubled by breathless except on strenuous execise 
1 Shortness of breath when hurrying on the level or walking 
up a slight hill 
2 Walks slower than people of the same age on the level 
because of breathlessness or has to stop for breath when 
walking at own pace on the level 
3 Stops for breath after walking about 100 m or after a few 
minutes on the level 
4 Too breathless to leave the house or breathless when 
dressing or undressing 
 
On top of that, base on the Malaysian guideline 2009 for COPD also they added the 
symptoms that may be present according to the level of COPD : 
 
Table 2: COPD stage and its symptoms 
COPD stage 
 
Symptoms that may be present 
1 ( Mild ) Chronic cough and sputum production 
may be present. At this stage, the 
individual is usually unaware that his or 
her lung function is abnormal. 
2 ( Moderate ) Dyspnoea typically on exertion, cough 
12 
 
and sputum production sometimes also 
present. This is the stage at which 
patients usually seek medical attention 
because of chronic respiratory symptoms 
or an exacerbation of COPD. 
3 ( Severe ) Greater dyspnoea, reduced exercise 
capacity, fatigue, and repeated 
exacerbations that almost always have 
an impact on the patient’s quality of life 
4 ( Very severe ) Respiratory failure may lead to cor 
pulmonale with signs which include 
elevation of the jugular venous pressure 
and pitting ankle oedema. At this stage, 
quality of life is markedly impaired and 
exacerbations may be life threatening. 
 
A multidimensional grading system, the BODE index  (Body mass index, 
airflow obstruction, dyspnoea and exercise capacity) have a better survival prediction 
in COPD patient than FEV1 alone(Bartolome R.Celli et al., 2004). This is because 
COPD is not just a disease confined to the lung, but have systemic effects (Agustı, 
2005) that would contributes to the COPD morbidities and mortalities that was not 
reflected by the FEV1 alone. The BODE index is a multidimensional 10 point scale in 
which higher scores indicate a higher risk of death.  
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Table 3: The BODE index score 
Variable Points on BODE index 
 0 1 2 3 
FEV1 ≥65 50-64 36-49 ≤35 
6 Minute Walk 
test ( meters ) 
≥350 250-349 150-249 ≤149 
MMRC 
Dyspnoeic 
score 
0-1 2 3 4 
Body Mass 
Index 
≥21  ≤21 
 
2.6.2 Six minutes walking test 
 The functional exercise capacity can be determine using the 6 minutes walking 
distance(Nilva Regina Gelamo Pelelegrino et al., 2009). This test is to evaluate 
objectively the functional exercise capacity for COPD patient. Subjective questions 
can be asked to assess functional capacity for example “How many flights of stairs 
can you climb” or “How far can you walk”, however this may overestimates or 
underestimates the true functional capacity of a patient. The initial walking test was 
developed in early 1960’s (Balke, 1963) by measuring the distance walked during a 
defined period of time. Later on, a 12 minutes field performance test was developed 
to evaluate the functional disability in chronic bronchitis patient (MC Gavin CR et al., 
1976).  
The 6 minutes walking test was developed to accommodate patient with 
COPD, where a 12 minutes walking test was too exhausting (Butland RJA et al., 
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1982). It is easier to administer, better tolerated and more reflective of activities of 
daily living than the other test(Solway S et al., 2001). This test measures the distance 
a patient can walk on a flat, hard ground in a period of 6 minutes. Optimal reference 
from healthy population samples using standardization 6mwd methods is not yet 
available. A mean of 630 metres was reported in healthy adults (Damien Stevens et 
al., 1999). Other study had found the mean of 580m for men and 500m for 
women(Miyamoto S et al., 2000). In COPD patient, the walking distance was found to 
be less in patient with more severe stage; a mean of 207±40m in stage 4 COPD as 
compared to a mean of 455±37m in stage 1 COPD(Eleni Ischaki et al., 2007). 
 However in Malaysia the walking distance for the 6 minutes walking test was 
somewhat more less than other countries. The mean walking distance is about 
308.9±160.6m (Ayiesah Ramli et al., 2008) in a study regarding pulmonary 
rehabilitation in stable COPD patients at Hospital Universiti Kebangsaan Malaysia. 
While comparing among countries(C. Casanova et al., 2011) the mean distance 
among different countries are 446±99m for Spain, 225±40m for Venezuela and 
311±121m for United States.  
There are a lot factors that make the reference range of the 6mwd to be 
underestimated or overestimated. Factors that influence the variability of the test was 
stated in the American Thoracic Society Statement for the 6 minutes walking test as 
stated below: 
Table 4: 6MWD sources of variability 
Reducing factor Increasing factor 
Shorter height 
Older age 
Taller height 
Male sex 
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Higher body weight 
Female sex 
A shorter corridor 
Pulmonary Disease 
Cardiovascular disease 
Musculoskeletal disorder 
High motivation 
Patient who had previously performed 
the test 
 
Just taken medication for the disabling 
disease 
 
Oxygen supplement 
 
 
2.6.3 Body composition 
Body composition refers to the proportion of fat and fat free mass in the body.  
Fat mass contains the metabolic inactive energy store while fat free mass contains 
the metabolic active organs especially the skeletal muscle. Reduction in this skeletal 
muscle will directly cause the reduction in lung function and general functional 
activity. People who have higher proportion of fat free mass compared to body fat are 
considered healthier as they have less weight related problem.  
A large study involving 1218 participants (Charlotte Landbo et al., 1999) 
demonstrated COPD mortality was significantly higher in underweight subjects as 
defined by a low body mass index. Further analysis of the study shows that BMI and 
COPD mortality was significantly higher in patient with FEV1 less than 50%. This 
indicates that there is a strong interaction between BMI with COPD severity and its 
prognosis. 
But we still need to consider that body mass index (BMI) includes both the fat 
mass and fat free mass index. Therefore measuring BMI alone could be an incorrect 
way to measure the skeletal muscle mass in COPD patient. Fat free mass index 
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(FFMI) in the other hand would reflect better prediction of decline in the skeletal 
muscle mass.  
Therefore the usage of fat free mass index rather than body mass index could 
be a more significant parameter of prognostic value in COPD patient. This is 
observed from COPD patient from Copenhagen City Heart Study(Jorgen Vestbo et 
al., 2006), where even though they have normal BMI, 26.1% of them had a low fat 
free mass index. In term of looking into COPD severity, they observed that patients 
with normal BMI in stage 3 and 4 COPD according to the FEV1 value, 50% of them 
had a low FFMI. Comparing from stage 1 to stage 4 COPD, the FFMI also shows a 
decreasing trend from mean of 17.2kg/m2 to 16.1kg/m2 respectively. 
Both of the above study used bioelectric impedance analysis to measure the 
body composition. The observation of reduction in body composition related to COPD 
prognosis was also found when other method being used. This was shown by using 
the measurement of mid thigh muscle area using CT scan(Karine Marquis et al., 
2002). They found that depletion in mid thigh muscle area was a strong predictor of 
mortality in COPD patient with FEV1 less than 50%.  
 
2.6.4 C-Reactive Protein  
C-reactive protein is an acute phase protein which is found in the blood in 
response to inflammation. It is synthesized by the liver in response to factors 
released by fat cells. Its physiological role is to bind to phospholipids expressed on 
the surface of the dead or dying cells in order to activate the complement system via 
the C1Q complexes. In COPD patient it is expected to be elevated as the 
pathogenesis of COPD includes inflammatory reaction. As it is an acute phase 
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reactant, CRP will be elevated in patients who have exacerbation of COPD or 
infection, therefore patient in this study only includes those who are stable whereby 
they were not having any acute exacerbation for the past three months prior to study 
date as the inclusion criteria.  
Recent advances are looking at local and systemic biomarkers in correlation 
with the lung function assessment. CRP in advance COPD were raised in 48 among 
102 patients and in these patients their resting energy expenditure were higher and 
the six minutes walking test were lower(R. Broekhuizen et al., 2006). 
This is supported by other studies that shows not only CRP but Interleukin 6, 
fibrinogen and tumour necrosis factor (Jorgen Vestbo et al., 2006) are elevated in 
even at a mild stage of COPD and it correlates well with low fat free mass index 
which is an independent predictor of mortality despite the lung function test value. 
 Mainly the studies in CRP level were looking at the highly sensitive CRP level. 
When comparing the level between stable COPD patient and control, it was noted to 
be significantly higher ( 4.1 mg/l versus 1.8mg/l, respectively p < 0.001) (J.P. de 
Torres et al., 2006). Other than that it was also shown that the distance of walking 
was significantly reduced in patient with higher CRP level.  
 
2.7 Systemic effect of COPD  
 COPD as defined before is not a disease only confined to the lung but also 
have systemic effects that complicate the disease. This systemic illnesses leads to a 
pronounced deterioration in health status and diminished quality of life (R.Shoup et 
al., 1997). Although the underlying mechanism of  these systemic effects are unclear, 
there is growing evidence that it involves systemic inflammation, tissue hypoxia, 
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oxidative stress and inactivity due to skeletal muscle dysfunction(Abdullah A. eid et 
al., 2001).  
The extra pulmonary condition or the co-morbid illness that are associated 
with COPD are; cachexia and malnutrition (Daniel A King et al., 2008); normochromic 
normocytic anaemia (T. Similowski et al., 2006); skeletal muscle wasting and 
peripheral muscle dysfunction (Noritoshi Nagaya et al., 2005); ischemic heart 
disease(José Luis Izquierdo et al., 2010), osteopenia, osteoporosis and bone 
fractures (Lidwien Graat-Verboom et al., 2009); sleep disorders, anxiety and 
depression (Wanning Xu et al., 2008). The relationships between these pulmonary 
and non pulmonary co morbidities are not fully understood, and this further 
complicates the assessment of disease severity and prognosis. 
 
2.7.1 Nutritional abnormalities and weight loss 
The observation of nutritional abnormalities in COPD had well been 
established for many years. Among the earliest  evidence of a relationship between 
body weight and COPD emerged from a study investigating metabolic imbalances in 
severe bronchial obstruction (Vandenbergh E et al., 1967). Nutritional abnormalities 
includes alterations in caloric intake, basal metabolic rate, intermediate metabolism 
and body composition(Schols, 2000).  
There are a growing interest in this parameter as it had been proven that 
nutritional abnormalities reflected by the body mass index and fat free mass index to 
be an independent predictor of mortality (Jorgen Vestbo et al., 2006), functional 
capacity  and also in expressing disease severity (Eleni Ischaki et al., 2007). The 
study by Jorgen Vestbo in 2006, found that patient who is in the lowest 10th 
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percentile of the general populations for fat free mass index have a higher risk of 
COPD related mortality.  
The study by Eleni Ischaki in 2007 showed that there were a significant 
relationship between FFMI and the 6 minutes walking distance (P< 0.0001). This 
significance however was poorly observed if BMI was used to see the correlation with 
the 6 minutes walking distance (P>0.01). Therefore body composition measurement 
is an important abnormality that would be use for screening and preventive measure 
in COPD patient. 
Unexplained weight loss occurs in about 50% of patients with severe COPD 
and chronic respiratory failure, but it can also be seen in about 10-15 % of patients 
with mild to moderate disease (Creutzberg., 1998). Loss of skeletal muscle mass is 
the main cause of weight loss in COPD while loss of fat mass contributes to a lesser 
extent. The pathophysiological cause of weight loss is most likely attributed to a high 
metabolic rate that is not compensated by a corresponding increase in caloric 
intake(Creutzberg., 1998). 
 Because of the close relation between nutritional abnormalities and prognosis 
of COPD, further study was done to correct the nutritional aspect of patient. A meta-
analysis (Ivone Martins Ferreira et al., 1998) looking at 272 references, found that 
nutritional support by giving caloric supplement for at least 2 weeks, had no effect on 
improving anthropometric measures, pulmonary function, respiratory muscle strength 
and functional exercise capacity in stable COPD patients. Further study in 2002, 
contradict this meta-analysis, whereby oxandrolone ( an anabolic steroid ) had been 
shown that it can restore lean body mass in COPD patient after four months of 
clinical trial(Shing-Shing Yeh et al., 2002).  
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2.7.2 Skeletal muscle dysfunction  
 Muscle mass dysfunction is an important feature of COPD despite the 
spirometry value. It has significant contribution to patient symptoms and prognosis. 
The presence of muscle dysfunction was first recognised in a study demonstrating 
that many patients with COPD have limited exercise capacity owing to skeletal 
muscle dysfunction(Killian., 1992). 
 The pathogenesis of skeletal muscle dysfunction in COPD patient is probably 
due to inactivity, tissue hypoxia and systemic inflammation. Cytokines such as 
tumour necrotic factor alpha and oxidative stress can contribute to the protein 
inactivation and degradation, resulting in dysfunction, atrophy and apoptosis (Alvar 
G. N. Agustí et al., 2002). Other than that, the treatment for COPD itself by giving 
steroids can leads to muscle dysfunction by causing skeletal muscle 
myopathy(Decramer., 1994). 
 Although research in attributing the cause of the muscle dysfunction is still 
going on, we do know now that it has important consequences including exercise 
limitation, reduced quality of life and reduced survival. Therefore as skeletal muscle 
depletion is potentially treatable, compared to the pulmonary component; it has a 
major role as a target in treating COPD patient. The benefit of this approach is mostly 
by using pulmonary rehabilitation as it improves symptoms and reduced disability 
(Linda Nici et al., 2006). This would further improve patient quality of life. The 
mechanism towards pulmonary rehabilitation is largely due to skeletal muscle 
adaptation to physical training (Maltais., 1996). 
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2.8 Measurement of nutrition in COPD 
 Nutritional measurement is based on the body composition which includes the 
body mass index and the fat free mass index. The term malnutrition and cachexia are 
often used interchangeably and define as body mass index. In assessing nutritional 
state for COPD  patient, the simple measurement of weight adjusted for height which 
is the body mass index may not characterized the overall nutritional state because in 
COPD patient the cachexia is more related to the loss of muscle mass which 
correlate better to the prognosis even when they have a normal BMI (Annemie M.W.J 
Schols et al., 2005). 
 Schols and co-workers distinguished three different types of impaired nutrition: 
semi starvation ( low BMI with normal or above normal fat free mass index ), muscle 
atrophy ( low fat free mass index and normal or above normal BMI ) and cachexia ( 
low BMI and low fat free mass index ). They found that patients in the semi starvation 
group had better survival compared to the other two groups indicating that a lower fat 
free mass index better predicts the mortality. They also found out that patients with 
GOLD stage IV had the highest prevalence of cachexia compared to others.  
 There is no gold standard method for the measurement of fat free mass index. 
The choice of measurement method for body composition includes dual energy X-ray 
absorptiometry ( DEXA ), bioelectric impedance analysis ( BIA ) and skin fold 
anthropometry ( SFA ). DEXA has been suggested as a suitable clinical reference 
method for the measurement of body composition (Van Loan and PR., 1992). 
However because of its cost and inconvenience to patient, the bedside evaluation by 
using SFA and BIA is the preferred choice.  
Compared to DEXA, the sensitivity for detecting nutritional depletion was 86% 
for BIA and 74% for SFA, while the specificity is 88% for BIA and 98% for SFA (M.C 
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Steiner et al., 2002). Therefore BIA causes underestimation of fat free mass index 
relative to DEXA, while SFA causes overestimation. BIA estimates the total body 
water from measurement of whole body impedance. Fat free mass is calculated from 
total body water using a prediction equation derived from comparison with a 
reference method. 
 In defining the level of fat free mass index there are still ongoing study to 
define the standard reference range. In a large study involving 5635 young healthy 
Caucasians adults  (Schutz., 2002),  the median fat free mass index were 18.9kg/m2 
for males and 15.4 kg/m2 for females. To see the variation among different ethnic at 
different countries, further study was also done (Hull., 2011) involving Caucasian, 
African American, Hispanic and Asian in 2010 involving 1339 healthy subjects age 
from 18 to 110 years. The total body fat, total fat free mass and bone mineral density 
was measured using dual energy X-ray absorptiometry. In this cross sectional study 
they found that the mean fat free mass index according to the ethnic group for males 
is 20.5 for Caucasian, 21.1 for African American, 20.6 for Hispanic and 18.8 for 
Asian. While for female subjects it was 16.6 for Caucasian, 17.4 for African 
American, 17.9 for Hispanic and 15.0 for Asian. These differences were statistically 
significance among the ethnic groups (P< 0.05). 
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3.0 Objective of the study :  
Primary objective : 
To determine the association between body composition with severity of disease in 
Chronic Obstructive Pulmonary Disease patients. 
Secondary objectives : 
1. To determine the association between BMI and severity of disease in COPD 
patients. 
2. To determine the association between FFMI and severity of disease in COPD 
patients. 
3. To determine the association between functional activity and severity of 
disease in COPD patients. 
4. To determine the association between C-reactive protein (CRP) level and 
severity of disease in COPD patients.  
 
 
 
 
 
 
 
 
 
